Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183261 · ClinicalTrials.gov registry record · Phase 2
Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection
A Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 20
- Study locations
NCT00183261: Completed Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00183261 is a Phase 2 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 25 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00183261, a Phase 2 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether the HIV vaccine MRKAd5 HIV-1 gag/pol/nef followed by treatment interruption can increase immune system function in adults with acute or recent HIV infection who have started taking anti-HIV drugs.
Conditions Studied
Interventions
- BIOLOGICAL MRKAd5 HIV-1 gag/pol/nef
- BIOLOGICAL MRKAd5 HIV-1 gag/pol/nef placebo
Study Locations (20)
New South Wales
- 407 Doctors CRS - Surry Hills
- Holdsworth House Medical Practice CRS - Darlinghurst
- St. Vincent's Hospital CRS - Darlinghurst
- Taylor Square Private Clinic CRS - Darlinghurst
- AIDS Research Initiative, Darlinghurst CRS - Darlinghurst
North Carolina
- Unc Aids Crs - Chapel Hill
- UNC, Chapel Hill AIEDRP - Chapel Hill
- Duke Univ. Med. Ctr. Adult CRS - Durham
- Dumc Aiedrp - Durham
California
- Ucsd Aiedrp - San Diego
- Ucsf Aiedrp - San Francisco
- LA Biomedical Research Institute at Harbor-UCLA AIEDRP - Torrance
New York
- Beth Israel Med. Ctr., ACTU - New York
- Aaron Diamond AIDS Research Ctr. AIEDRP - New York
Other
- 407 Doctors (Australia) AIEDRP - Sydney
- AIDS Research Initiative (Australia) AIEDRP - Sydney
Colorado
- Univ. of Colorado Health Sciences Ctr. AIEDRP - Denver
Massachusetts
- Fenway Community Health Ctr. CRS - Boston
Missouri
- Washington U CRS - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
What the finished NCT00183261 record still lists
NCT00183261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which MRKAd5 HIV-1 gag/pol/nef is the first listed.
NCT00183261 names 20 study sites across 9 states, led by New South Wales, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT00183261 about?
NCT00183261 is a clinical study titled "Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection". The purpose of this study is to determine whether the HIV vaccine MRKAd5 HIV-1 gag/pol/nef followed by treatment interruption can increase immune system function in adults with acute or recent HIV infection who have started taking anti-HIV drugs.
What is the current status of trial NCT00183261?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2006-03. Estimated completion is 2010-10.
What conditions does trial NCT00183261 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00183261?
The interventions under investigation include: MRKAd5 HIV-1 gag/pol/nef (BIOLOGICAL), MRKAd5 HIV-1 gag/pol/nef placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT00183261?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00183261 being conducted?
This trial has 20 study locations across California, Colorado, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00183261's enrollment target sits among peer trials
25 461st of 542 higher than 74 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia